Browsing Tag

Alaunos Therapeutics

Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the…

Eli Pacheco Sep 21, 2022 0

First patient achieved a confirmed partial response with 51.2% tumor regression with TCR-T cell persistence ongoing at 3 months post infusionSleeping Beauty TCR-T cell therapy had a…

Health

Alaunos Therapeutics to Participate in Upcoming Investor Conferences in September

Eli Pacheco Sep 7, 2022 0

HOUSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced…

Health

Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer…

Eli Pacheco Aug 25, 2022 0

HOUSTON, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced…

Health

Alaunos Therapeutics and the National Cancer Institute Extend Cooperative Research…

Eli Pacheco Jun 27, 2022 0

HOUSTON, June 27, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced…

Health

Alaunos Therapeutics to Present Trials in Progress Poster for its TCR-T Library Phase…

Eli Pacheco May 27, 2022 0

HOUSTON, May 26, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced a…

Health

Alaunos Therapeutics to Present at American Society of Gene and Cell Therapy 25th…

Eli Pacheco May 3, 2022 0

Preclinical data to be presented highlights the potential ability to generate mbIL-15 TCR-T cells targeting hotspot mutations expressed in solid tumors with enhanced survival capacity…